leriglitazone: PPAR gamma agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
hydroxypioglitazone : A member of the class of thiazolidenediones that is the hydroxy derivative of pioglitazone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 4147757 |
| CHEMBL ID | 1267 |
| CHEBI ID | 82937 |
| SCHEMBL ID | 4098326 |
| Synonym |
|---|
| 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| ZINC01482947 |
| CHEMBL1267 |
| hydroxypioglitazone |
| chebi:82937 , |
| min-102 |
| leriglitazone |
| 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| FT-0643388 |
| 146062-44-4 |
| hydroxy pioglitazone (m-iv) |
| AKOS015856344 |
| 2,4-thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]- |
| 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione |
| OXVFDZYQLGRLCD-UHFFFAOYSA-N |
| 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione |
| SCHEMBL4098326 |
| DTXSID30399914 |
| who 10868 |
| unii-k824x25aya |
| A1-01710 |
| all-ambo-5-((4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazole-2,4(3h,5h)-dione |
| K824X25AYA , |
| 2,4-thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)- |
| leriglitazone [inn] |
| leriglitazone [usan] |
| J-008187 |
| 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione |
| Q27156475 |
| pioglitazone, hydroxy |
| DB15021 |
| CS-0067030 |
| HY-117727 |
| D11603 |
| leriglitazone (usan/inn) |
| 1-hydroxypioglitazone |
| hydroxy pioglitazone-d5 (major) (m-iv) |
| bdbm50530214 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metabolites 6-9 have been identified after dosing of rats and dogs." | ( Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. Colca, JR; Fisher, RM; Kletzein, RF; Parker, TT; Tanis, SP, 1996) | 0.29 |
| Role | Description |
|---|---|
| human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| thiazolidinediones | A thiadiazolidine in which the 1,3-thiazolidine ring is substituted by two oxo groups. |
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 (µMol) | 13.0000 | 0.0050 | 1.2051 | 10.0000 | AID1614508 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Ki | 1.2000 | 0.0000 | 0.3790 | 5.6000 | AID1614505 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 1.3600 | 0.0000 | 0.9922 | 10.0000 | AID1614504; AID1614507; AID1614512 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Kd | 0.7080 | 0.0012 | 0.9531 | 4.9800 | AID1614511 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Activity | 2.6100 | 0.1200 | 2.0087 | 5.5000 | AID1614509; AID1614510 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleoplasm | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| cytosol | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| RNA polymerase II transcription regulator complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| chromatin | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| receptor complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1614509 | Displacement of FITC-TRAP220 peptide from human 6His-tagged PPARgamma isoform 1 LBD (203 to 477 residues) expressed in Escherichia coli BL21(DE3) by FP assay (Rvb = 2.7 uM) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614507 | Activation of human 6His-tagged PPARgamma isoform 1 LBD (203 to 477 residues) expressed in Escherichia coli BL21(DE3) assessed as increase in FITC-TRAP220 peptide recruitment after 1 hr by FITC/TR-FRET assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614505 | Displacement of fluormone PanPPAR green tracer ligand from human 6His-tagged PPARgamma isoform 1 LBD (203 to 477 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by TR-FRET assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614508 | Displacement of FITC-NCoR1 peptide from human 6His-tagged PPARgamma isoform 1 LBD (203 to 477 residues) expressed in Escherichia coli BL21(DE3) after 1 hr by FITC/TR-FRET assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614504 | Transactivation of chimeric Gal4 yeast DBD fused-PPARgamma LBD (unknown origin) expressed in HEK293T cells co-expressing PPRE after 18 hrs by luciferase reporter gene assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID106695 | Compound was evaluated for Antihyperglycemic activity in KKAy mice, glucose level for the treated group (T) over the anti-hyperglycaemic activity | 1996 | Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26 | Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. |
| AID1614511 | Binding affinity to human 6His-tagged PPARgamma LBD expressed in Escherichia coli BL21(DE3) using FITC-NTKNHPMLMNLLKDNPAQD peptide by isothermal titration calorimetry | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614510 | Displacement of FITC-NCoR1 peptide from human PPARgamma LBD expressed in Escherichia coli BL21(DE3) by FP assay (Rvb = 1.7 uM) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614512 | Transactivation of full length human PPARgamma2 expressed in HEK293T cells co-expressing PPRE after 18 hrs by luciferase reporter gene assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| AID1614506 | Binding affinity to human 6His-tagged PPARgamma isoform 1 LBD (203 to 477 residues) expressed in Escherichia coli BL21(DE3) assessed as unfolding temperature at 1 molar equiv concentration by thermal denaturation assay (Rvb = 45.6 degC) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||